Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs
The DOI matches its Crossref record; 248 of the 249 references it cites were found in a registry or an index.
Abstract
There is a high prevalence of painful diabetic polyneuropathy (pDPN) with around one-third of all patients with diabetes suffering from pDPN. pDPN has debilitating consequences, with a major impact on morbidity and quality of life. Unfortunately, there is no globally licenced pharmacotherapy that modulates the underlying disease mechanisms to prevent or halt the progression of diabetic neuropathy. The cornerstone of treatment therefore remains optimising glycaemic control and cardiovascular risk factors, and symptom control. Evidence from placebo-controlled studies has shown that antidepressants and anticonvulsants are effective for alleviating pDPN. Current clinical guidelines recommend the treatment of pDPN through the use of amitriptyline (tricyclic antidepressant), duloxetine (serotonin norepinephrine reuptake inhibitor), gabapentin and pregabalin (α2-δ ligands), tramadol and tapentadol (μ receptor agonists and norepinephrine reuptake inhibitors) and topical agents such as capsaicin (transient receptor potential V1 receptor desensitizer), although the latter is known to cause degeneration of small nerve fibers. pDPN can be difficult to treat, which frustrates healthcare providers, patients and caregivers. There is an additional need for clinical trials of novel therapeutic agents and optimal combinations for the management of pDPN. This article reviews the pharmacological management of pDPN, emerging therapies, the difficulties of placebo response in clinical trials and n…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [554]
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [554]
In the citing paper
“Electrophysiological testing or referral to a neurologist is rarely needed for diagnosis, except in situations where the clinical features are atypical, the diagnosis is unclear, and a different etiology is suspected.547,554,565”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [554]
In the citing paper
“Moderate improvements in pain are considered to be approximately 30–50% pain relief, whereas a good outcome is considered greater than 50% pain relief [10].”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · cited 1×
“In the Diabetes Control and Complications Trial (DCCT), the prevalence of DPN in the conventional treatment arm was ~ 20%, whilst in the intensive treatment arm it was 10% after 5 years, in those with type 1 diabetes (T1D) who were non-neuropathic at baseline [17].”
BackgroundPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 2×
“3) for amitriptyline in the treatment of neuropathic pain [55, 111].”
BackgroundThe validation of visual analogue scales as ratio scale measures for chronic and experimental pain
Price, D. D., McGrath, P. A., Rafii, A., & Buckingham, B. (1983) · Pain · doi:10.1016/0304-3959(83)90126-4 · Cited by 3,921
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 6×
“ER extended release, NM not mentioned, NR not recommended, NICE National Institute of Clinical Excellence[30], AACE American Association of Clinical Endocrinologists [32], EFNS European Federation of Neurological Societies Task Force [34], AAN American Academy of Neurology [33], ADA American Diabetes Association [31]…”
BackgroundInfluentialClinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain
Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., Donovan, M. I., Fishbain, D. A., Foley, K. M., Fudin, J., et al. (2009) · The Journal of Pain · doi:10.1016/j.jpain.2008.10.008 · Cited by 2,192
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873 · cited 3×
“ER extended release, NM not mentioned, NR not recommended, NICE National Institute of Clinical Excellence[30], AACE American Association of Clinical Endocrinologists [32], EFNS European Federation of Neurological Societies Task Force [34], AAN American Academy of Neurology [33], ADA American Diabetes Association [31]…”
BackgroundBackonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,533
Young, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502 · cited 1×
“5% of the population had DPN, with increasing prevalence related to older age and duration of diabetes [14].”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323 · cited 3×
“Deep burning pain is considered a good discriminator of painful neuropathy as suggested by the EURODIAB study [19].”
BackgroundSelf-citationEffects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy
Max, M. B., Lynch, S. A., Muir, J., Shoaf, S. E., Smoller, B., & Dubner, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205073261904 · Cited by 1,117 · cited 9×
“Co-prescription with serotonergic drugs (e.g. selective serotonin reuptake inhibitors (SSRIs) and TCAs) increases the risk of serotonin syndrome and should be avoided, particularly monoamine oxidase inhibitors or tramadol [123].”
BackgroundInfluential
Research works printed but not linked: 7
- IDF. IDF diabetes atlas. 8th Edition ed: Web; 2017.
- Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci. 2014;11(3–4):37–42.
- Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828–49. · DOI · Paper page
- McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013(8). · DOI · Paper page
- Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140(21–22):297–306.
- Basit A, Basit KA, Fawwad A, Shaheen F, Fatima N, Petropoulos IN, et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diabetes Res Care. 2016;4(1):e000148. · DOI
- H.J. M. Placebo and control event rate. In: McQuay H.J., editor. Systematic reviews in pain research: methodology redefined. IASP Press, Seattle; 2008. pp. 51–6.
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Self-citationDiabetic neuropathy: cutting-edge research and future directions
Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02175-1 · Cited by 234
“23 However, their use is limited by anticholinergic side effects, especially in elderly patients and those with cardiovascular disease.”
Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms?
Calcutt, N. A. (2020) · Pain · doi:10.1097/j.pain.0000000000001922 · Cited by 159
“In contrast to degenerative neuropathy, there are a number of therapies approved by regulatory agencies to alleviate pain in diabetes and others that are used off-label.(9,18) However, it is notable that none were developed to target diabetes-specific mechanisms, although efficacy is both unpredictable and restricted…”
BackgroundMethodManagement of diabetic neuropathy
Cernea, S., & Raz, I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154867 · Cited by 115
Metadata
- Authors
- Alam, U., Sloan, G., & Tesfaye, S.
- Affiliations
- University of Liverpool (GB)
- Royal Hallamshire Hospital (GB)
- Corresponding author
- Alam, Uazman
- Venue
- Drugs
- Published
- 2020-02-10
- Volume
- 80
- Issue
- 4
- Pages
- 363-384
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3005601005
- Cited by
- 104
- References
- 249
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 9 · 2023: 13 · 2022: 20 · 2021: 18 · 2020: 17
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- painful diabetic polyneuropathy, neuropathic pain, pharmacotherapy, antidepressants, antiepileptic drugs, amitriptyline, duloxetine, gabapentin, pregabalin, tramadol, tapentadol, capsaicin, topical agents, new drugs, placebo response, treatment response biomarkers
- MeSH terms
- Anticonvulsants, Antidepressive Agents, Diabetic Neuropathies, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs. https://app.cochat.ai/papers/10.1007/s40265-020-01259-2
- The paper
- Alam, U., Sloan, G., & Tesfaye, S. (2020). Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs. Drugs. https://doi.org/10.1007/s40265-020-01259-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.